MYND LIFE SCIENCS INC - MYNDF STOCK NEWS

MYND Diagnostics, a subsidiary of MYND Life Sciences, has launched a clinical validation study for its proprietary MAP biomarker test aimed at aiding the diagnosis and monitoring of Multiple Sclerosis (MS). The study, expected to start in Q1 2022, will quantify MAP levels in MS patients' blood samples compared to controls. Successful results could lead to an FDA approval submission in H2 2022, making the test available through healthcare providers. The global MS therapeutic market was valued at $22.99 billion in 2018 and is projected to reach $28 billion by 2026.

MYND Life Sciences has announced the initiation of a clinical validation study for its proprietary biomarker testing in Alzheimer's Disease (AD) diagnostics. The study, conducted by its subsidiary MYND Diagnostics, aims to utilize the MAP biomarker to enhance early diagnosis and monitoring of AD. The validation is set to commence in Q1 2022, with anticipated FDA submission for approval in H2 2022. Currently, around 44 million people are affected by AD worldwide, and the diagnostics market was valued at USD 6.6 billion in 2020, projected to reach USD 9 billion by 2026.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) has signed a binding letter of intent with MYND Diagnostics Inc. for a clinical research collaboration. This aims to study the relationship between diagnostic results using MYND's proprietary anti-inflammatory peptide biomarker (MAP) and improved patient outcomes in mental health. The initial clinical trials will focus on patients with post-COVID-19 mental health symptoms, utilizing Revitalist's network of over 2,300 patients. The goal is to submit MAP to the FDA for approval in Q2 2022, enhancing diagnostic accuracy and treatment efficacy.

MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announces a binding LOI with Revitalist Lifestyle and Wellness to collaborate on clinical research. This partnership aims to study the MAP biomarker’s effectiveness in diagnosing and monitoring mental health, particularly in patients experiencing post-COVID-19 symptoms like 'Brain Fog.' The objective is to provide a more objective diagnostic tool for healthcare providers and to gain FDA approval by Q2 2022. MYND anticipates generating revenue through research and aims to expand its mental health studies leveraging Revitalist's extensive clinic network.

MYND Life Sciences Inc. has announced significant changes to its Board of Directors. Aaron Bowden, a founding board member, has resigned, with the company expressing gratitude for his contributions. In his place, Scott L. Nicoll has been appointed as an independent director and interim Chair of the Audit Committee. Nicoll brings extensive legal and governance experience as a partner at Panorama Legal LLP and chair of Food Banks BC. The board is optimistic that his leadership will enhance the company's governance.

MYND Life Sciences (CSE: MYND, OTC: MYNDF) announced its agreement to acquire intellectual property rights from Cava Healthcare for the use of psychedelics in treating dementia, including Alzheimer's disease. The deal involves 450,000 common shares at a deemed price of $0.85 each and $120,000 in cash. MYND will also pay a yearly royalty of $240,000 or 4% of net sales. This acquisition aims to strengthen MYND's position in psychedelic treatments for neurodegenerative conditions.

MYND Diagnostics Inc. announced its participation in a proposed clinical trial to evaluate the efficacy of psilocybin-assisted psychotherapy for treatment-resistant depression (TRD). The trial aims to secure a portion of a $15 million fund from the Australian government and will employ MYND's proprietary biomarker technology. Led by Professor Paul Fitzgerald of Monash University, the phase 2b trial will assess the safety and efficacy of psilocybin treatments. If successful, it could lead to a multi-site phase 3 trial for regulatory approval within 12 months.

MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF) will present at the VirtualInvestorConferences.com Psychedelics Conference on October 13, 2021, at 2:00 pm ET. CEO Dr. Lyle Oberg will lead the live, interactive event, allowing investors to ask questions in real-time. A recorded version will be available later for those who cannot attend. Recent company highlights include the launch of MYND Diagnostics Ltd., a $3 million convertible debenture offering, and a publication in The Lancet on Alzheimer's research. Interested investors can register here.

MYND Life Sciences has announced the formation of its diagnostic biomarker division through a wholly-owned subsidiary, MYND Diagnostics Ltd., aimed at enhancing diagnosis and treatment for patients with Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD). The subsidiary plans to generate revenue by Q2 2022 with the commercialization of the MYND Anti-inflammatory Peptide (MAP) biomarker. The global biomarkers market is forecast to grow from USD 41.47 billion in 2019 to USD 115.45 billion by 2027, enhancing MYND Diagnostics' potential in this expanding sector.